Bladder Cancer Clinical Trial

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

Summary

Bladder cancer is a common disease with high rates of mortality, especially at advanced stages. Neo-adjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy is considered standard of care for patients with muscle invasive disease, as NAC improves surgical outcomes in these patients. However, some patients are ineligible for cisplatin-based chemotherapy due to other medical issues. Although a combination of carboplatin and gemcitabine has been used with limited success, most patients proceed directly to cystectomy without realizing the potential survival benefit afforded by NAC. Intravenous ascorbate (vitamin C) administration (IVC) has been shown to improve both carboplatin and gemcitabine-based therapy in other models. This trial will add IVC to gemcitabine/carboplatin chemotherapy to evaluate whether co-treatment will increase therapeutic efficacy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) Performance Status = 0 -- 2
Cisplatin-ineligible, muscle invasive bladder cancer
Adequate organ and marrow functions
Women of child-bearing potential and men with partners of child-bearing potential must agree to use protocol specified forms of birth control

Exclusion Criteria:

Patient simultaneously enrolled in any therapeutic clinical trial
Current or anticipated use of other investigational agents while participating in this study
Psychiatric illness/social situations that would limit compliance with study requirements
Pregnant or breast feeding. There is a potential for congenital abnormalities and for this regimen to harm breast feeding infants
Histology of pure adenocarcinoma, pure squamous cell carcinoma, or pure small cell carcinoma in the TURBT sample
Prior systemic chemotherapy (prior intravesical therapy is allowed) and/ or prior radiation therapy to the urinary bladder
Uncontrolled intercurrent illness
Current consumption of tobacco products
History of glucose-6-phosphate dehydrogenase (G6PD) deficiency

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

16

Study ID:

NCT04046094

Recruitment Status:

Active, not recruiting

Sponsor:

University of Kansas Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

The University of Kansas Cancer Center (KUCC)
Fairway Kansas, 66205, United States
The University of Kansas Medical Center
Kansas City Kansas, 66160, United States
The University of Kansas Cancer Center, Westwood Campus
Kansas City Kansas, 66205, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

16

Study ID:

NCT04046094

Recruitment Status:

Active, not recruiting

Sponsor:


University of Kansas Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.